Exactech has acquired intelligent patient wearables and digital communication solutions maker Muvr Labs to expand its Active Intelligence Platform of Smart Technologies portfolio.
The Muvr platform has been designed to help surgeons to connect with their joint replacement patients throughout the journey of care.
It has patient wearables, mobile device applications and chatbot texting, which enables surgeons to remotely monitor patient recovery.
In addition, the wearable device delivers real-time data to the healthcare team on each patient’s experience and recovery.
Not just analysing the steps taken, these wireless sensors can measure the individual’s range of motion.
With the patent-protected, self-calibrating design, patients can handle the wearable on their own without needing in-person office visits and minimal healthcare team intervention.
Exactech CEO Darin Johnson said: “We are incredibly excited to join efforts with the team at Muvr to transform the relationship between patients and surgeons through this comprehensive care management platform.
“This acquisition demonstrates our continued commitment to delivering personalised, data-driven solutions to improve patient outcomes.”
Moreover, with the help of Muvr’s web application, surgeons can easily detect at-risk patients and can be connected remotely for a follow-up.
The surgeon / patient chatbot conducts text conversations to provide reminders and answer common patient queries.
The technology can potentially reduce the workload of the surgical team while obtaining pain scores, exercise adherence, mobility metrics, and survey information.
Pilot launch of the Muvr technology is expected to take place early next year with a full release by the end of the year.
US-based Orthopaedic surgeon Alexander Sah said: “Patients are attracted to the technology because they know our team is monitoring their progress; remarkably, this has caused my patients to take more ownership of their recovery.
“It’s also very simple to use because it doesn’t require in-office calibration, which allows patients to use the sensors at home, unsupervised.”